Integrum AB Series B
Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoidi… Read more
Integrum AB Series B (INTEG-B) - Total Assets
Latest total assets as of September 2025: Skr179.05 Million SEK
Based on the latest financial reports, Integrum AB Series B (INTEG-B) holds total assets worth Skr179.05 Million SEK as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Integrum AB Series B - Total Assets Trend (2013–2024)
This chart illustrates how Integrum AB Series B’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Integrum AB Series B - Asset Composition Analysis
Current Asset Composition (December 2024)
Integrum AB Series B's total assets of Skr179.05 Million consist of 49.6% current assets and 50.4% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 19.5% |
| Accounts Receivable | Skr33.26 Million | 16.4% |
| Inventory | Skr27.44 Million | 13.5% |
| Property, Plant & Equipment | Skr5.18 Million | 2.6% |
| Intangible Assets | Skr59.82 Million | 29.4% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Integrum AB Series B's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Integrum AB Series B's current assets represent 49.6% of total assets in 2024, a decrease from 71.7% in 2013.
- Cash Position: Cash and equivalents constituted 19.5% of total assets in 2024, down from 27.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 2.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 29.4% of total assets.
Integrum AB Series B Competitors by Total Assets
Key competitors of Integrum AB Series B based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Integrum AB Series B - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Integrum AB Series B generates 0.45x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Integrum AB Series B is currently not profitable relative to its asset base.
Integrum AB Series B - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.44 | 6.34 | 3.63 |
| Quick Ratio | 1.88 | 4.62 | 2.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr48.21 Million | Skr 81.95 Million | Skr 22.69 Million |
Integrum AB Series B - Advanced Valuation Insights
This section examines the relationship between Integrum AB Series B's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.44 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 23.3% |
| Total Assets | Skr203.25 Million |
| Market Capitalization | $10.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values Integrum AB Series B's assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Integrum AB Series B's assets grew by 23.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Integrum AB Series B (2013–2024)
The table below shows the annual total assets of Integrum AB Series B from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr203.25 Million | +23.29% |
| 2023-12-31 | Skr164.86 Million | -0.19% |
| 2022-12-31 | Skr165.17 Million | -8.46% |
| 2021-12-31 | Skr180.44 Million | +384.93% |
| 2020-12-31 | Skr37.21 Million | +15.57% |
| 2019-12-31 | Skr32.20 Million | +29.28% |
| 2018-12-31 | Skr24.90 Million | -5.60% |
| 2017-12-31 | Skr26.38 Million | +33.42% |
| 2016-12-31 | Skr19.77 Million | +94.44% |
| 2015-12-31 | Skr10.17 Million | +58.49% |
| 2014-12-31 | Skr6.42 Million | -25.77% |
| 2013-12-31 | Skr8.64 Million | -- |